Clinical Trial Search

Phase 3 N=26 Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

Epilepsy

Primary: Incidence of Treatment Emergent Adverse Events (TEAEs) During Evaluation Period — 78.9; 71.4 percentage of subjects

UCB Pharma SA Results Aug 2017 26.9% serious AE View details

Phase 3 N=222 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil

Chronic Hepatitis C Infection

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 96.4 percentage of participants

AbbVie Results Aug 2017 2.7% serious AE View details

Phase 3 N=62 PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot

Venous Thromboembolism · Postpartum

Primary: Feasibility of Recruitment and Trial Operations. — 0.9; 0.9 participants per site per month

Ottawa Hospital Research Institute Results Aug 2017 3.2% serious AE View details

Phase 3 N=450 Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Candidiasis, Invasive · Candidemia · Mycoses

Primary: Percentage of Participants With Overall Response of Success at the End of Intravenous Therapy (EOIV) as Determined by the Data Review Committee (DRC) Based on the…

Astellas Pharma Inc Results Aug 2017 49.6% serious AE View details

Phase 3 N=955 Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Primary: Progression-Free Survival (PFS) — 22.1; 22.3 months — p=0.1590

Amgen Results Aug 2017 45.9% serious AE View details

Phase 3 N=192 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma

HIV-1 Infection · Kaposi's Sarcoma

Primary: Kaposi Sarcoma (KS) Status at Week 48 Compared to Study Entry — 43; 47; 13; 9 Participants — p=0.911

Advancing Clinical Therapeutics Globally for… Results Jul 2017 35.8% serious AE View details

Phase 3 N=2,124 A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Atrial Fibrillation · Percutaneous Coronary Intervention

Primary: Percentage of Participants With Clinically Significant Bleeding — 15.7; 16.6; 24.0 percentage of participants — p=<0.001

Janssen Scientific Affairs, LLC Results Jul 2017 34.9% serious AE View details

Phase 3 N=74 Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients

Congenital Bleeding Disorder · Haemophilia B

Primary: Incidence of Inhibitory Antibodies Against Factor IX Defined as Titre Equal to or Above 0.6 BU (Bethesda Units) — 0; 0 Number of subjects

Novo Nordisk A/S Results Jul 2017 5.4% serious AE View details

Phase 3 N=159 A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males

Adult Male Hypogonadism

Primary: The Percentage of Subjects Whose Average Concentration (Cave(0-24)) Serum Total Testosterone Levels Are ≥300 and ≤1050 ng/dL — 76.1 percentage of subjects

Ferring Pharmaceuticals Results Jul 2017 3.1% serious AE View details

Phase 3 N=160 Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

HCV · Hepatitis C Infection · Genotype 4

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm — 94.0; 96.8; 93.1 percentage of participants

AbbVie Results Jul 2017 2.5% serious AE View details

Phase 3 N=231 LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Non-Small Cell Lung Cancer

Primary: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) — 5.4; 1.6 months — p=<0.001

Novartis Pharmaceuticals Results Jul 2017 44.8% serious AE View details

Phase 3 N=302 Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort

Abdominal Pain

Primary: Change of the Mean Pain Intensity Score Measured on a Visual Analogue Scale (VAS) Within 3 Days (and Within 1 Day) - ANCOVA — -2.48; -2.45; -2.36; -2.31 Units on a scale…

Boehringer Ingelheim Results Jul 2017 0.0% serious AE View details

Phase 3 N=213 Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

Congenital Bleeding Disorder · Haemophilia A

Primary: Frequency of Development of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU)/mL) — 0; 0; 0; 0 subjects

Novo Nordisk A/S Results Jul 2017 19.3% serious AE View details

Phase 3 N=512 A Multi-Center Study Evaluating the Safety of AC-170 0.24%

Atopic Disease (Including Allergic Conjunctivitis)

Primary: Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 1 (Day 1) — 0.9; 0.5; 0.7; 0.3 units on a scale

Aciex Therapeutics, Inc. Results Jul 2017 0.4% serious AE View details

Phase 3 N=155 Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

Venous Leg Ulcers

Primary: Wound Closure — 17; 23 participants

Healthpoint Results Jul 2017 9.0% serious AE View details